NantHealth to Showcase New Oncology Solution Suite, Advanced Medication Adherance Solution and the Latest in Device Connectivity at HIMSS 2017 Annual Conference

Products transform the way critical diseases like cancer are known and treated

NantHealth to exhibit in booth #5561 and provide live demos on the Interoperability Showcase™ Floor

ORLANDO, Fla.--()--NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today that it will be exhibiting its new suite of oncology solutions at booth #5561 and providing demos at the Interoperability Showcase floor at booth #9000 Hall F, during the HIMSS 2017 Annual Conference & Exhibition in Orlando, Florida. Recognized as one of the premiere healthcare industry conferences, HIMSS17 brings together healthcare professionals from across the globe.

Throughout HIMSS 2017, NantHealth will showcase its extensive Oncology Suite aimed at improving the effectiveness and efficiency of specialty care through clinical and IT solutions. The solution takes a holistic approach to patient care via molecular profiling, precision medicine decision support, care coordination and outcomes measurement providing a continuous feedback loop which supports the goal of higher quality care at a reduced cost. The solutions also support the Centers for Medicare & Medicaid Services’ (CMS) Innovation Center’s Oncology Care Model (OCM) program. The goal of the OCM is to achieve better care, smarter spending and healthier people. To support this model, NantHealth’s portfolio of solutions provides oncologists with the tools necessary to ensure that 21st century treatments are deployed across the country.

Among its suite of next-generation solutions is NantHealth’s latest rendition of the Vitality® Glowcap®, a medication adherence system that tracks, reminds and alerts patients to reinforce them to take their prescribed medication, which now utilizes Bluetooth Low Energy (BLE) 4.0 communications. As the pace of technology innovation in healthcare continues to gain momentum, connected care has become critical to improving the patient experience, as it ensures a seamless delivery of health IT services at the point of care.

In addition to showcasing this latest connected care solution, NantHealth will also be exhibiting the following solutions at booth #5561:

  • Oncology Solutions
    • GPS Cancer™: a comprehensive molecular profile providing key insights based on the unique biology of a patient’s tumor—from the DNA to the RNA to the protein.
    • eviti®: the evidence-based treatment intelligence and web-based oncology decision support platform, which was recently named #1 Clinical Decision Support solution for 2016 by Black Book Market Research.
  • Patient-Provider Engagement Solution
    • Health Notebook: connects patients with their providers and health records to improve satisfaction and motivate patients to participate in their own care.
    • Care Coordination: helps clinicians manage patient care across multiple care settings.
    • Provider Portal: gives physicians a unified view of critical patient data across the enterprise, across the continuum, across the episode of care—despite disparate systems and varying locations.
  • Connected Care Solutions
    • DeviceConX®: captures patient data from medical devices, and delivers that data to an EHR, CIS, or other data repository—quickly and accurately.
    • VitalsConX®: a flexible, intuitive rounding solution that automates a patient’s vitals collection workflow.
  • Payer Engagement Solutions
    • NaviNet® Open: the industry’s leading payer-provider collaboration platform.

While at the Interoperability Showcase in kiosk #9000 Hall F, NantHealth will demonstrate joint use cases led by HealthShare Exchange of Southeastern PA with Independence Blue Cross, University of Pennsylvania, NextGen and Comcast called “On the Road to Cancer Care 2020” addressing how technology will impact the future of cancer treatment. NantHealth will also deliver a “Scheduled Surgery and Recovery” use case with several key industry stakeholders, which follows a patient from a scheduled surgery through recovery demonstrating how interoperability is present throughout the journey. Additional use cases being displayed include:

  • i-Home Use Case: featuring NantHealth’s Care Coordination and Vitality solutions.
  • Outpatient Use Case: highlighting EMR integration with eviti cancer clinical learning solution.
  • OR Use Case: demonstrating the Connected Care DeviceConX solution.
  • IoT Demo Wall: demonstrating the state-of-the-art Connected Care Vitality solution for medication adherence.

“As we continue on the path toward advancing cancer care, we’re constantly thinking about the ecosystem of influence that will help us achieve this goal,” said Dr. Patrick Soon-Shiong, CEO and founder of NantHealth. “Whether its personalized medicine identified via GPS Cancer or enabling providers to have access to treatment intelligence databases, there are many components that are responsible for working together to find the ways we can fight this longstanding battle against cancer. Health IT certainly plays a major role in connecting payers, providers and patients and it is a necessity if we’re ever going to defeat this disease.”

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.


Jen Hodson, 562-397-3639


Jen Hodson, 562-397-3639